General Information
Adjuvant therapy
Advanced disease
Note: Separate PDQ summaries on Screening for Colorectal Cancer and Prevention
of Colorectal Cancer are also available.
Note: Some citations in the text of this section are followed by a level of
evidence. The PDQ editorial boards use a formal ranking system to help the
reader judge the strength of evidence linked to the reported results of a
therapeutic strategy. (Refer to the PDQ summary on Levels of Evidence for more
information.)
Cancer of the rectum is a highly treatable and often curable disease when
localized. Surgery is the primary treatment and results in cure in
approximately 45% of all patients. The prognosis of rectal cancer is clearly
related to the degree of penetration of the tumor through the bowel wall and
the presence or absence of nodal involvement. These 2 characteristics form the
basis for all staging systems developed for this disease. Preoperative staging
procedures include digital rectal examination, computed tomographic scan or
magnetic resonance imaging scan of the abdomen and pelvis, endoscopic
evaluation with biopsy, and endoscopic ultrasound (EUS).[1] EUS is an accurate
method of evaluating tumor stage (up to 95% accuracy) and the status of the
perirectal nodes (up to 74% accuracy). Accurate staging can influence therapy
by helping to determine which patients may be candidates for local excision
rather than more extensive surgery and which patients may be candidates for
preoperative chemotherapy and radiation therapy to maximize the likelihood of
resection with clear margins. Many other prognostic markers have been
evaluated retrospectively in the prognosis of patients with rectal cancer,
although most, including allelic loss of chromosome 18q or thymidylate synthase
expression, have not been prospectively validated.[2-4] Microsatellite
instability, also associated with hereditary nonpolyposis rectal cancer, has
been shown to be associated with improved survival independent of tumor stage
in a population-based series of 607 patients less than 50 years of age with
colorectal cancer.[5] Racial differences in overall survival after adjuvant
therapy have been observed, without differences in disease-free survival,
suggesting that comorbid conditions play a role in survival outcome in
different patient populations.[6] A major limitation of surgery is the
inability to obtain wide radial margins because of the presence of the bony
pelvis. In those patients with disease penetration through the bowel wall
and/or spread into lymph nodes at the time of diagnosis, local recurrence
following surgery is a major problem and often ultimately results in death.[7]
The radial margin of resection of rectal primaries may also predict for local
recurrence.[8]
Because of the frequency of the disease, the demonstrated slow growth of
primary lesions, the better survival of patients with early-stage lesions, and
the relative simplicity and accuracy of screening tests, screening for rectal
cancer should be a part of routine care for all adults over the age of 50
years, especially those with first-degree relatives with colorectal cancer.[9]
There are groups that have a high incidence of colorectal cancer. These groups
include those with hereditary conditions, such as familial polyposis,
hereditary nonpolyposis colon cancer (HNPCC) or Lynch Syndrome Variants I and II, and ulcerative colitis.[10] (Refer to the PDQ summary on Genetics of
Colorectal Cancer for more information.) Together they account for 10% to 15%
of colorectal cancers. Patients with HNPCC reportedly have better prognoses in
stage-stratified survival analysis than patients with sporadic colorectal
cancer, but the retrospective nature of the studies and the possibility of
selection factors make this observation difficult to interpret.[11] [Level of
evidence: 3iiiA] More common conditions with an increased risk include: a
personal history of colorectal cancer or adenomas, first degree family history
of colorectal cancer or adenomas, and a personal history of ovarian,
endometrial, or breast cancer.[12,13] These high-risk groups account for only
23% of all colorectal cancers. Limiting screening or early cancer detection to
only these high-risk groups would miss the majority of colorectal cancers.[14]
(Refer to the PDQ summaries on Screening for Colorectal Cancer and Prevention
of Colorectal Cancer for more information.)
Following treatment of rectal cancer, periodic evaluations may lead to the
earlier identification and management of recurrent disease.[15-18] However,
the impact of such monitoring on overall mortality of patients with recurrent
rectal cancer is limited by the relatively small proportion of patients in whom
localized, potentially curable metastases are found. To date, there have been
no large-scale randomized trials documenting the efficacy of a standard,
postoperative monitoring program.[19-23] Carcinoembryonic antigen (CEA) is a
serum glycoprotein frequently used in the management of patients with rectal
cancer. A review of the use of this tumor marker suggests: that CEA is not
useful as a screening test; that postoperative CEA testing be restricted to
patients who would be candidates for resection of liver or lung metastases; and
that routine use of CEA alone for monitoring response to treatment not be
recommended.[24] However, the optimal regimen and frequency of follow-up
examinations are not well defined, since the impact on patient survival is not
clear and the quality of data is poor.[21-23] New surveillance methods
including CEA immunoscintigraphy and positron tomography are under clinical
evaluation.[25]
Although a large number of studies have evaluated various clinical,
pathological, and molecular parameters with prognosis, as yet, none have had a
major impact on prognosis or therapy.[26] Clinical stage remains the most
important prognostic indicator.
Gastrointestinal stromal tumors can occur in the rectum. (Refer to the PDQ
summary on Adult Soft Tissue Sarcoma Treatment for more information.)
Adjuvant therapy
Patients with stage II or III rectal cancer are at high risk for local and
systemic relapse. Adjuvant therapy should address both problems. Most trials
of preoperative or postoperative radiation therapy alone have shown a decrease
in the local recurrence rate but no definite effect on survival;[15,27-30]
although a Swedish trial has shown a survival advantage from preoperative
radiation therapy compared to surgery alone.[31] [Level of evidence: 1iiA] Two
trials have confirmed that fluorouracil (5-FU) plus radiation therapy is
effective and may be considered standard treatment.[27-29] In these trials,
combined modality adjuvant treatment with radiation therapy and chemotherapy
following surgery also resulted in local failure rates lower than with either
radiation therapy or chemotherapy alone. An analysis of patients treated with
postoperative chemotherapy and radiation therapy suggests that these patients
may have more chronic bowel dysfunction compared to those who undergo surgical
resection alone.[32] Improved radiation planning and techniques can be used to
minimize treatment-related complications. These techniques include the use of
multiple pelvic fields, prone positioning, customized bowel immobilization
molds (belly boards), bladder distention, visualization of the small bowel with
oral contrast, and the incorporation of three-dimensional or comparative
treatment planning.[33,34] Ongoing clinical trials comparing preoperative and
postoperative adjuvant chemoradiotherapy should further clarify the impact of
either approach on bowel function and other important quality-of-life issues
(e.g., sphincter preservation) in addition to the more conventional endpoints
of disease-free and overall survival.
Advanced disease
Radiation therapy in rectal cancer is palliative in most situations but may
have greater impact when used perioperatively. Palliation may be achieved in
approximately 10% to 20% of patients with 5-FU. Several studies suggest an
advantage when leucovorin is added to 5-FU in terms of response rate and
palliation of symptoms, but not always in terms of survival.[35-41] Irinotecan
(CPT-11) has been approved by the Food and Drug Administration for the
treatment of patients whose tumors are refractory to 5-FU.[42-45]
Participation in clinical trials is appropriate. A number of other drugs are
undergoing evaluation for the treatment of colon cancer.[46] Oxaliplatin,
alone or combined with 5-FU and leucovorin, has also shown activity in 5-FU
refractory patients.[47-50]
References
- Snady H, Merrick MA: Improving the treatment of colorectal cancer: the role of EUS. Cancer Invest 16 (8): 572-81, 1998.
[PUBMED Abstract]
- McLeod HL, Murray GI: Tumour markers of prognosis in colorectal cancer. Br J Cancer 79 (2): 191-203, 1999.
[PUBMED Abstract]
- Jen J, Kim H, Piantadosi S, et al.: Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331 (4): 213-21, 1994.
[PUBMED Abstract]
- Lanza G, Matteuzzi M, Gafá R, et al.: Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 79 (4): 390-5, 1998.
[PUBMED Abstract]
- Gryfe R, Kim H, Hsieh ET, et al.: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342 (2): 69-77, 2000.
[PUBMED Abstract]
- Dignam JJ, Colangelo L, Tian W, et al.: Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst 91 (22): 1933-40, 1999.
[PUBMED Abstract]
- Heald RJ, Ryall RD: Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1 (8496): 1479-82, 1986.
[PUBMED Abstract]
- de Haas-Kock DF, Baeten CG, Jager JJ, et al.: Prognostic significance of radial margins of clearance in rectal cancer. Br J Surg 83 (6): 781-5, 1996.
[PUBMED Abstract]
- Cannon-Albright LA, Skolnick MH, Bishop DT, et al.: Common inheritance of susceptibility to colonic adenomatous polyps and associated colorectal cancers. N Engl J Med 319 (9): 533-7, 1988.
[PUBMED Abstract]
- Thorson AG, Knezetic JA, Lynch HT: A century of progress in hereditary nonpolyposis colorectal cancer (Lynch syndrome). Dis Colon Rectum 42 (1): 1-9, 1999.
[PUBMED Abstract]
- Watson P, Lin KM, Rodriguez-Bigas MA, et al.: Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members. Cancer 83 (2): 259-66, 1998.
[PUBMED Abstract]
- Ransohoff DF, Lang CA: Screening for colorectal cancer. N Engl J Med 325 (1): 37-41, 1991.
[PUBMED Abstract]
- Fuchs CS, Giovannucci EL, Colditz GA, et al.: A prospective study of family history and the risk of colorectal cancer. N Engl J Med 331 (25): 1669-74, 1994.
[PUBMED Abstract]
- Winawer SJ: Screening for colorectal cancer. Cancer: Principles and Practice of Oncology Updates 2(1): 1-16, 1987.
- Martin EW Jr, Minton JP, Carey LC: CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma. Ann Surg 202 (3): 310-7, 1985.
[PUBMED Abstract]
- Bruinvels DJ, Stiggelbout AM, Kievit J, et al.: Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 219 (2): 174-82, 1994.
[PUBMED Abstract]
- Lautenbach E, Forde KA, Neugut AI: Benefits of colonoscopic surveillance after curative resection of colorectal cancer. Ann Surg 220 (2): 206-11, 1994.
[PUBMED Abstract]
- Khoury DA, Opelka FG, Beck DE, et al.: Colon surveillance after colorectal cancer surgery. Dis Colon Rectum 39 (3): 252-6, 1996.
[PUBMED Abstract]
- Safi F, Link KH, Beger HG: Is follow-up of colorectal cancer patients worthwhile? Dis Colon Rectum 36 (7): 636-43; discussion 643-4, 1993.
[PUBMED Abstract]
- Moertel CG, Fleming TR, Macdonald JS, et al.: An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 270 (8): 943-7, 1993.
[PUBMED Abstract]
- Rosen M, Chan L, Beart RW Jr, et al.: Follow-up of colorectal cancer: a meta-analysis. Dis Colon Rectum 41 (9): 1116-26, 1998.
[PUBMED Abstract]
- Desch CE, Benson AB 3rd, Smith TJ, et al.: Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol 17 (4): 1312, 1999.
[PUBMED Abstract]
- Benson AB 3rd, Desch CE, Flynn PJ, et al.: 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol 18 (20): 3586-8, 2000.
[PUBMED Abstract]
- Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 14 (10): 2843-77, 1996.
[PUBMED Abstract]
- Lechner P, Lind P, Goldenberg DM: Can postoperative surveillance with serial CEA immunoscintigraphy detect resectable rectal cancer recurrence and potentially improve tumor-free survival? J Am Coll Surg 191 (5): 511-8, 2000.
[PUBMED Abstract]
- Roth JA: p53 prognostication: paradigm or paradox? Clin Cancer Res 5 (11): 3345, 1999.
[PUBMED Abstract]
- O'Connell M, Wieand H, Krook J, et al.: Lack of value for methyl-CCNU (MeCCNU) as a component of effective rectal cancer surgical adjuvant therapy: interim analysis of intergroup protocol 86-47-51. [Abstract] Proceedings of the American Society of Clinical Oncology 10: A-403, 134, 1991.
- Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group. J Clin Oncol 10 (4): 549-57, 1992.
[PUBMED Abstract]
- Moertel CG: Chemotherapy for colorectal cancer. N Engl J Med 330 (16): 1136-42, 1994.
[PUBMED Abstract]
- Kachnic LA, Willett CG: Radiation therapy in the management of rectal cancer. Curr Opin Oncol 13 (4): 300-6, 2001.
[PUBMED Abstract]
- Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 336 (14): 980-7, 1997.
[PUBMED Abstract]
- Kollmorgen CF, Meagher AP, Wolff BG, et al.: The long-term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function. Ann Surg 220 (5): 676-82, 1994.
[PUBMED Abstract]
- Koelbl O, Richter S, Flentje M: Influence of patient positioning on dose-volume histogram and normal tissue complication probability for small bowel and bladder in patients receiving pelvic irradiation: a prospective study using a 3D planning system and a radiobiological model. Int J Radiat Oncol Biol Phys 45 (5): 1193-8, 1999.
[PUBMED Abstract]
- Gunderson LL, Russell AH, Llewellyn HJ, et al.: Treatment planning for colorectal cancer: radiation and surgical techniques and value of small-bowel films. Int J Radiat Oncol Biol Phys 11 (7): 1379-93, 1985.
[PUBMED Abstract]
- Petrelli N, Douglass HO Jr, Herrera L, et al.: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 7 (10): 1419-26, 1989.
[PUBMED Abstract]
- Erlichman C, Fine S, Wong A, et al.: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6 (3): 469-75, 1988.
[PUBMED Abstract]
- Doroshow JH, Multhauf P, Leong L, et al.: Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8 (3): 491-501, 1990.
[PUBMED Abstract]
- Poon MA, O'Connell MJ, Wieand HS, et al.: Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9 (11): 1967-72, 1991.
[PUBMED Abstract]
- Valone FH, Friedman MA, Wittlinger PS, et al.: Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol 7 (10): 1427-36, 1989.
[PUBMED Abstract]
- Borner MM, Castiglione M, Bacchi M, et al.: The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 9 (5): 535-41, 1998.
[PUBMED Abstract]
- Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 10 (6): 896-903, 1992.
[PUBMED Abstract]
- Rothenberg ML, Eckardt JR, Kuhn JG, et al.: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14 (4): 1128-35, 1996.
[PUBMED Abstract]
- Conti JA, Kemeny NE, Saltz LB, et al.: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14 (3): 709-15, 1996.
[PUBMED Abstract]
- Rougier P, Van Cutsem E, Bajetta E, et al.: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352 (9138): 1407-12, 1998.
[PUBMED Abstract]
- Cunningham D, Pyrhönen S, James RD, et al.: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352 (9138): 1413-8, 1998.
[PUBMED Abstract]
- Von Hoff DD: Promising new agents for treatment of patients with colorectal cancer. Semin Oncol 25 (5 Suppl 11): 47-52, 1998.
[PUBMED Abstract]
- de Gramont A, Vignoud J, Tournigand C, et al.: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33 (2): 214-9, 1997.
[PUBMED Abstract]
- Bleiberg H, de Gramont A: Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol 25 (2 Suppl 5): 32-9, 1998.
[PUBMED Abstract]
- Cvitkovic E, Bekradda M: Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol 26 (6): 647-62, 1999.
[PUBMED Abstract]
- Giacchetti S, Perpoint B, Zidani R, et al.: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18 (1): 136-47, 2000.
[PUBMED Abstract]
Back to Top
Next Section > |